Current state of adjuvant immunotherapy for high-risk urothelial cancer
“This is the perfect situation for the development of biomarkers to inform [patient selection for] adjuvant treatment with immune checkpoint blockade,” says Matthew Galsky, MD.
In an interview at the 2022 SUO Annual Meeting, Matthew Galsky, MD, discussed the current state of the use of adjuvant immunotherapy for the treatment of patients with urothelial cancer at high risk of recurrence after radical surgery. Randomized clinical trials exploring the role of adjuvant immunotherapy in this setting have yielded somewhat mixed results, so Galksy says biomarkers are needed to determine optimal patient selection.
Galsky is a professor of Medicine and director of Genitourinary Medical Oncology at the Icahn School of Medicine, Mount Sinai, and the co-director of the Center of Excellence for Bladder Cancer and associate director for translational research at the Tisch Cancer Institute.
KIM-1 emerges as biomarker for MRD, atezolizumab benefit in renal cell carcinoma
June 3rd 2024Circulating kidney injury molecule-1 (KIM-1) may be a biomarker for minimal residual disease, disease recurrence, and benefit from adjuvant atezolizumab in patients with renal cell carcinoma at increased risk of recurrence, according to a retrospective analysis of the phase 3 IMmotion010 trial.
